Abstract
Merkel cell carcinoma (MCC) is a highly malignant skin cancer with a propensity for local recurrence and regional lymph node metastases. Once recurrence occurs, tumour progression becomes hard to be controlled. Overexpression of programmed death‐ligand 1 (PD‐L1) in MCC correlates with better clinical outcomes, in contrast to other solid carcinomas, e.g., malignant melanoma. The successful results of treatment with the immune checkpoint inhibitor avelumab for metastatic MCC highlight this unusual relationship between MCC and PD‐L1 expression.
This article is protected by copyright. All rights reserved.
https://ift.tt/2OJBd0A
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου